Clinical trials in Potsdam – page 51

1 819 clinical trials in Potsdam, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Potsdam at a glance

1 819

clinical trials

Research sites1

Quick filters

1 819 trials in Potsdam

Open in trial search

Tuberous sclerosis complex

Recruiting

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carbamazepine
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Small cell lung cancer+1

Recruiting

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Acute lymphocytic leukaemia+4

Recruiting

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Trametinib
Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Aop Orphan Pharmaceuticals GmbH

Contact Research Centre

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Mechanical ventilation+2

Recruiting

Study on Early Sedation with Dexmedetomidine vs. Placebo for Older Critically Ill Patients on Ventilators

Registered drug

Study on Early Sedation with Dexmedetomidine vs. Placebo for Older Critically Ill Patients on Ventilators

Registered drug

Germany

Participants:65+ years
Sponsor:Monash University

Contact Research Centre

Partial lipodystrophy

Recruiting

Study on the Effects of Metreleptin for Patients with Partial Lipodystrophy

Registered drugNo placebo

Study on the Effects of Metreleptin for Patients with Partial Lipodystrophy

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Metreleptin
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Dementia+5

Recruiting

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Flutemetamol (18F)
Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Contact Research Centre

Chronic lymphocytic leukaemia

Recruiting

Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

InvestigationalNo placebo

Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tislelizumab
Sponsor:University Of Cologne

Contact Research Centre

Hereditary angioedema

Recruiting

Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

InvestigationalNo placebo

Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:Intellia Therapeutics Inc.

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug

Germany

Participants:0–17 years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

Early-stage breast cancer interventions
HPV-positive oropharyngeal cancer treatments
Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

Actinic keratosis treatments
Hidradenitis suppurativa therapy
Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

Relapsing-remitting MS treatments
Novel therapeutic approaches
Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

Lipoprotein management
Cholesterol reduction therapies
Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Back to Germany All countries